Crinetics Pharmaceuticals, INC 8-K filings

Crinetics Pharmaceuticals has submitted a New Drug Application to the FDA for paltusotine, a once-daily oral treatment for acromegaly.

Crinetics Pharmaceuticals has announced that its Chief Commercial Officer, James Hassard, will be departing from the company effective October 14, 2024.

Crinetics Pharmaceuticals announced its second quarter 2024 financial results, highlighted by progress in its clinical programs and a leadership transition.

Crinetics Pharmaceuticals has entered into a sales agreement to offer and sell up to $350 million of its common stock through an at-the-market offering.

Crinetics Pharmaceuticals held its annual meeting on June 7, 2024, where stockholders elected two Class III directors, ratified the selection of BDO USA, P.C. as the independent accounting firm, and approved executive compensation on an advisory basis.

Crinetics Pharmaceuticals shared promising initial data for atumelnant in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and presented new data supporting paltusotine as a potential first-choice treatment for acromegaly.

Crinetics Pharmaceuticals announced that abstracts for the ENDO 2024 conference were released earlier than expected, including data from a Phase 2 study of atumelnant for Congenital Adrenal Hyperplasia.

Crinetics Pharmaceuticals announced positive financial results for Q1 2024, highlighted by progress in clinical trials for paltusotine and atumelnant, and a $350 million private placement.

Crinetics Pharmaceuticals will present five abstracts at the ENDO 2024 meeting, showcasing advancements in their atumelnant and paltusotine clinical development programs.

Crinetics Pharmaceuticals has adopted an Excess Deferral Plan, effective April 1, 2024, allowing eligible employees and directors to defer compensation.

Crinetics Pharmaceuticals announced positive topline results from its Phase 3 PATHFNDR-2 study, demonstrating that oral paltusotine significantly improved IGF-1 levels and acromegaly symptoms compared to placebo.

Crinetics Pharmaceuticals reports positive topline results from its Phase 2 study of paltusotine, showing significant reductions in carcinoid syndrome symptoms.

Crinetics Pharmaceuticals has successfully raised approximately $350 million through a private placement of common stock to institutional and accredited investors.

Crinetics Pharmaceuticals reported positive clinical trial results for its lead drug candidate, paltusotine, and secured $350 million in private financing to extend its cash runway into 2028.